FY2025 · ended Dec 31, 2025 · Revenue $61.24M, +11.1% YoY · Filed Mar 31, 2026
Fortress Biotech, Inc. (FBIO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $61.2 million and net income of $6.8 million. As of Jun 30, 2026 it held $196.6 million in cash and investments and $48.7 million in total debt.
Revenue (TTM)
$66.85M
+20.7% vs year-ago TTM
Net income (TTM)
$111.82M
+859.1% vs year-ago TTM
Operating cash flow (TTM)
$125.92M
+257.2% vs year-ago TTM
Free cash flow
$-80.19M
+37.5% vs prior year
EPS (TTM)
$3.25
+457.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
31.36M
+12.4% vs prior year
Net cash
$147.86M
as of Jun 30, 2026
Operating margin
-43.6%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- FBIO (Nasdaq), FBIOP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bay Harbor Islands, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1429260
- Former names
- Fortress Biotech, Inc. (until Oct 29, 2026); CORONADO BIOSCIENCES INC (until Apr 27, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $61.2M | $55.1M | $59.7M | $71.0M | $63.1M |
| Operating income | -$70.2M | -$110.4M | -$142.3M | -$203.6M | -$188.5M |
| Net income | $6.8M | -$46.0M | -$60.6M | -$86.6M | -$64.7M |
| Diluted EPS | -$0.07 | -$2.69 | -$8.47 | -$15.97 | — |
| Operating cash flow | -$65.8M | -$80.2M | -$128.2M | -$179.4M | -$116.5M |
| Free cash flow | — | -$80.2M | -$128.3M | -$182.1M | -$121.1M |
| Total assets | $185.5M | $144.2M | $167.5M | $294.3M | $396.5M |
| Total liabilities | $123.4M | $145.9M | $165.9M | $244.3M | $170.6M |
| Stockholders' equity | $49.9M | $22.7M | $22.5M | $41.7M | $108.7M |
| Cash and investments | $79.4M | $57.3M | $80.9M | $178.3M | $305.7M |
| Total debt | $67.2M | $75.3M | $81.7M | $115.7M | $66.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 1, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 23, 2026 | Jun 17, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 14, 2026 | May 14, 2026 |
All 886 Fortress Biotech, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.